Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Diagnostic Pathology
Lee, Hong Kyu HK; Kwon, Mi Jung MJ; Ra, Yong Joon YJ; Lee, Hee Sung HS; Kim, Hyoung Soo HS; Nam, Eun Sook ES; Cho, Seong Jin SJ; Park, Hye-Rim HR; Min, Soo Kee SK; Seo, Jinwon J; Choe, Ji-Young JY; Min, Kyueng-Whan KW; Kang, So Young SY
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
The Journal Of Investigative Dermatology
Posch, Christian C; Sanlorenzo, Martina M; Vujic, Igor I; Oses-Prieto, Juan A JA; Cholewa, Brian D BD; Kim, Sarasa T ST; Ma, Jeffrey J; Lai, Kevin K; Zekhtser, Mitchell M; Esteve-Puig, Rosaura R; Green, Gary G; Chand, Shreya S; Burlingame, Alma L AL; Panzer-Grümayer, Renate R; Rappersberger, Klemens K; Ortiz-Urda, Susana S
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Proceedings Of The National Academy Of Sciences Of The United States Of America
Posch, Christian C; Moslehi, Homayoun H; Feeney, Luzviminda L; Green, Gary A GA; Ebaee, Anoosheh A; Feichtenschlager, Valentin V; Chong, Kim K; Peng, Lily L; Dimon, Michelle T MT; Phillips, Thomas T; Daud, Adil I AI; McCalmont, Timothy H TH; LeBoit, Philip E PE; Ortiz-Urda, Susana S